Thus, whereas ovarian cancer cell lines can be clearly segregated into PD0332991-sensitive and resistant lines, IC50 values for current CDK2 inhibitors show a continuum within a narrow dose range that may be the result of non-cell cycle CDKs affected by SNS032 (CDK9) and dinaciclib (CDK5, 9). This evidence concerns the gene CDK9 and ovarian carcinoma.